TScan Therapeutics Inc (TCRX)
9.145
+0.24
(+2.75%)
USD |
NASDAQ |
May 20, 11:44
TScan Therapeutics Shareholders Equity (Quarterly): 122.97M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 122.97M |
| December 31, 2023 | 150.87M |
| September 30, 2023 | 168.96M |
| June 30, 2023 | 190.61M |
| March 31, 2023 | 78.02M |
| December 31, 2022 | 99.43M |
| September 30, 2022 | 116.66M |
| Date | Value |
|---|---|
| June 30, 2022 | 131.65M |
| March 31, 2022 | 145.69M |
| December 31, 2021 | 160.78M |
| September 30, 2021 | 174.07M |
| June 30, 2021 | -60.03M |
| March 31, 2021 | -49.92M |
| December 31, 2020 | -42.46M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-60.03M
Minimum
Jun 2021
190.61M
Maximum
Jun 2023
99.09M
Average
127.31M
Median
Shareholders Equity (Quarterly) Benchmarks
| AnaptysBio Inc | 47.78M |
| CEL-SCI Corp | 14.30M |
| AIM ImmunoTech Inc | 10.23M |
| IGC Pharma Inc | 9.053M |
| NovaBay Pharmaceuticals Inc | 0.16M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 240.83M |
| Total Liabilities (Quarterly) | 117.86M |
| Debt to Equity Ratio | 0.246 |
| Current Ratio | 5.233 |
| Net Debt Paydown Yield | -0.05% |